QRX-3 for Kidney Failure

(QRX-3 in ARF Trial)

Overseen By Ebima Okundaye, MD

Age: Any Age

Sex: Any

Trial Phase: Phase 2 & 3

Sponsor: Ebima Clifford Okundaye

Disqualifiers: High bleeding risk, Dialysis, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 4 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called QRX-3, a potential drug for individuals with kidney failure due to acute tubular necrosis, a condition where the kidney's filtering tubes sustain damage. Researchers aim to determine if adding QRX-3 to standard treatments improves patient recovery. Participants will be divided into two groups: one will receive QRX-3 with their usual care, while the other will receive a placebo (a harmless pill) with standard care for comparison. Suitable candidates for this trial are those hospitalized with sudden kidney failure and diagnosed with acute tubular necrosis by a kidney specialist. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

Do I have to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that QRX-3 is likely to be safe for humans?

Research has shown that QRX-3 has been tested in people with chronic kidney disease (CKD). Earlier studies examined QRX-3 for its potential to improve kidney function, and results indicated a positive effect at different stages of CKD.

Regarding safety, past users of QRX-3 did not experience major safety issues, suggesting that the treatment is generally well-tolerated. However, it is important to remember that this drug remains under study, and researchers continue to gather more information about its safety. For those considering joining a trial, safety remains a top priority, and ongoing studies aim to ensure the treatment's safety. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Unlike the standard of care for kidney failure, which typically involves medications to manage symptoms and dialysis for severe cases, QRX-3 offers a novel approach by targeting the underlying causes of kidney damage. Researchers are excited about QRX-3 because it works at the cellular level to repair and protect kidney tissues, potentially slowing or even reversing disease progression. Additionally, QRX-3 is taken orally, providing a more convenient option compared to treatments that require hospital visits or invasive procedures.

What evidence suggests that QRX-3 might be an effective treatment for kidney failure?

Research has shown that QRX-3, a new drug under study in this trial, may improve kidney function. Studies have found that QRX-3 can enhance kidney health, particularly in individuals with chronic kidney disease (CKD). It increases the availability of NAD+, a molecule crucial for energy production in the energy centers of kidney cells. This process can protect the nephrons, the functional units of the kidney, from further damage. In trials, QRX-3 consistently improved kidney function at various CKD stages. These findings suggest that QRX-3 could effectively treat acute tubular necrosis, a severe form of kidney failure. Participants in this trial will receive QRX-3 alongside standard therapy, while others will receive a placebo with standard therapy. ^{1 3 5 6 7}

Are You a Good Fit for This Trial?

This trial is for hospitalized children and adults diagnosed with acute tubular necrosis, a type of kidney failure. Participants must have a nephrologist's diagnosis or show high sodium excretion in urine tests. They can't join if they have urinary tract blockages, are at high risk of bleeding, already use dialysis regularly, or only have one functioning kidney.

Inclusion Criteria

I am currently hospitalized.

I am currently experiencing acute kidney failure.

I have been diagnosed with acute kidney injury by a kidney specialist.

Exclusion Criteria

I do not have kidney swelling or blockage in my urinary tract.

I am at high risk for bleeding.

I do not use dialysis.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive QRX-3 or placebo twice daily in addition to standard therapy

4 weeks

Daily visits for monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• QRX-3

Trial Overview The study is testing QRX-3 as a treatment for patients with acute tubular necrosis renal failure. It aims to see how effective this drug is in improving kidney function under these specific conditions.

How Is the Trial Designed?

Group I: Use of QRX-3 in addition to standard therapy Experimental Treatment 1 Intervention

QRX-3 drug orally as twice daily in addition to standard conventional therapy will be given to this group for 28 days

Group II: control group Placebo Group 1 Intervention

placebo twice daily will be given to this group in addition to standard therapy

Who Is Running the Clinical Trial?

Ebima Clifford Okundaye

Lead Sponsor

Trials

1

Recruited

2,400+

Citations

1. clinicaltrials.gov clinicaltrials.gov/study/NCT06866236

Study Details | NCT06866236 | Use of New Drug QRX-3 for ... In this study the investigators will evaluate the effect of intervention with this novel drug therapy on chronic kidney disease CKD population with slowly ...

2. researchgate.net researchgate.net/publication/374048507_Outcome_of_use_of_a_novel_Modulator_of_Oxidative_Phosphorylation_on_kidney_function_in_patients_with_Chronic_Kidney_disease/fulltext/650b027682f01628f0344699/Outcome-of-use-of-a-novel-Modulator-of-Oxidative-Phosphorylation-on-kidney-function-in-patients-with-Chronic-Kidney-disease.pdf

Outcome-of-use-of-a-novel-Modulator-of-Oxidative- ... The level of increase in renal function with QRX 3 drug use was similar in percentage between CKD stage. 3 and stage 4 but higher than the ...

3. clinicaltrials.gov clinicaltrials.gov/study/NCT07150338

Study Details | NCT07150338 | Outcome of Use of a Novel ... QRX-3 ( Eseronate ) is a formulated drug designed to supply and optimize NAD+ mitochondrial availability in order to target the loss of nephrons ...

4. centerwatch.com centerwatch.com/clinical-trials/listings/NCT06866236/use-of-new-drug-qrx-3-for-prevention-and-treatment-of-chronic-kidney-disease-progression

Use of New Drug QRX-3 for Prevention and Treatment ... In this study we evaluate the effect of intervention with this novel drug therapy on chronic kidney disease CKD population with slowly ...

5. withpower.com withpower.com/trial/phase-2-and-3-acute-kidney-injury-7-2025-4ded4

QRX-3 for Kidney Failure · Info for Participants It aims to see how effective this drug is in improving kidney function under these specific conditions. How Is the Trial Designed?

6. clinicaltrials.gov clinicaltrials.gov/study/NCT06948292

NCT06948292 | Role of QRX-3 in Chronic Kidney Disease ... It identifies the role of the intervention that participants receive. Types of arms include experimental arm, active comparator arm, placebo comparator arm, ...

7. withpower.com withpower.com/trial/phase-2-and-3-kidney-diseases-9-2025-ed6f9

QRX-3 for Chronic Kidney Disease (NAD agent Trial) This trial is for individuals with chronic kidney disease (CKD) who have shown a slow decline in kidney function over the past year, specifically less than a 20 ...